Triple-Drug cocktail aims to tackle Hard-to-Treat cancers

This study tests a combination of three drugs—tislelizumab, bevacizumab, and capecitabine—in people with advanced solid tumors. The trial focuses on two challenging groups: those whose cancers have stopped responding to immunotherapy and those with tumors that have spread to the brain or central nervous system. The goal is to find a safe dose and see if the combination can shrink tumors or slow their growth.